Executive Appointment Notice
Wellthera Co., Ltd. announces the following changes in its executive leadership, decided at the Extraordinary General Meeting of Shareholders held on 29 July 2025.
Effective as of 29 July 2025 (Shareholders’ EGM)
-
Retiring Representative Director (CEO): Mr. Taizō Imai, due to significantly impaired ability to carry out duties following a diagnosis of a designated intractable disease*
-
Promoted to Representative Director (CEO): Mr. Kazuo Maruyama
-
Appointed Director: Mr. Makoto Shimazaki
We extend our heartfelt gratitude to Mr. Imai for his dedicated service over the years and wish him improved health.
As We Move Forward
United in purpose, the entire team remains committed to accelerating our mission: to deliver breakthrough therapies as swiftly as possible to patients suffering from conditions for which no effective treatment currently exists. Your continued support is deeply appreciated.
Sincerely,
Wellthera Co., Ltd.
*Designated by the Japanese government as an intractable disease, multiple system atrophy (MSA) remains without an effective treatment to date (see footnote).